Sector Alpha Week of 2026-07-31
Sector Alpha — machine-written from the numbers · Data as of 2026-07-31

Dhanuka Agritech Ltd

DHANUKA
Pesticides/Agrochemicals

Dhanuka Agritech Ltd is cheap for a reason. The P/E sits at the 15th percentile of its own range, and the quarters are still getting worse.

The sharpest disagreement: annual EPS moved +25.6% against a −37.9% price move — the market has not yet caught up with the delivery.

The price is in a downtrend (40 weeks in) while the P/E sits at the 15th percentile of its own 11-year range. Underneath, the last four quarters read deteriorating — profit −27.3% year on year, and 69% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Topping out
fundamental trajectory, 12 quarters
Price
₹1,022
−37.9% 1Y
P/E
15.6×
15th pctile
of its own 11-year range
Revenue (Dec 25)
₹410 Cr
−7.9% YoY
Profit (Dec 25)
₹40.0 Cr
−27.3% YoY
Operating margin
14.0%
−3.0 pp YoY
ROCE
28%
FY25
ROIC
16.8%
vs WACC 12.0% → +4.8 pp
Cash conversion
69%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Dhanuka Agritech Ltd trades at ₹1,022, in a downtrend and 40 weeks into that stage. That is −10.7% against its own 200-day average. It sits at 15% of a 52-week range of ₹936 to ₹1,527. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (9 weeks and counting).

Today the stock is in a downtrend — week 40 of stage 4, confirmed. At ₹1,022 it trades −10.7% versus its 200-day average and sits at 15% of its 52-week range (₹936–₹1,527).

Jul 26: ₹1,022 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−10.7% versus the 200-day line, week 40 of stage 4
Price50-day avg200-day avg
S2S4S2S4₹1,937₹1,609₹1,281₹953₹625₹1,022₹1,145Jul 23May 24Feb 25Dec 25Jul 26
S2S4S2S4₹1,937₹1,609₹1,281₹953₹625₹1,022₹1,145Jul 23Feb 25Jul 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (551 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
Mar 16Jul 26

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +84% while the NIFTY 500 moved +274% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (9 weeks and counting; last ahead the week of 2026-06-17) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Dhanuka Agritech Ltd trades at 15.6× P/E, near the bottom of its own range — cheaper only 15% of the time. Its long-run median P/E is 19.2×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 15.6× is near the bottom of its own range — cheaper only 15% of the time, against a long-run median of 19.2× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.

P/E 15.6× vs a 19.2× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly (right axis). 10.5-year window; loss-period spikes above 34× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
near the bottom of its own range — cheaper only 15% of the time
P/EMedianEPS (TTM) (quarterly)
36.0×₹70.929.6×₹53.223.2×₹35.516.8×₹17.710.4×₹0.0×15.80×₹65Feb 16Oct 18Jun 21Feb 24Jul 26
36.0×₹70.929.6×₹53.223.2×₹35.516.8×₹17.710.4×₹0.0×15.80×₹65Feb 16Jun 21Jul 26
PEG 6.05 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Computed here as quarter-end P/E ÷ trailing-twelve-month EPS growth (only quarters with positive growth), because a reported quarterly PEG is not held for this stock. Last 11 quarters; values above 6 pinned at the top.
above 1.0, the multiple already banks the growth
PEGPEG = 1.0
6.4×4.9×3.4×1.9×0.4××6.00×Q4 FY23Q2 FY24Q1 FY25Q3 FY25Q2 FY26
6.4×4.9×3.4×1.9×0.4××6.00×Q4 FY23Q1 FY25Q2 FY26
P/E
15.6×
15th percentile of 11y
PEG
1.34
derived from 3-year earnings growth

Why the multiple sits where it does: over the past year annual EPS moved +25.6% against a −37.9% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the +1.5%/yr price move, ~+7.9%/yr came from earnings growth and ~−6.4 pp from the multiple (compressing); over 10y, of the +4.4%/yr price move, ~+11.6%/yr came from earnings growth and ~−7.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Topping out

Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Dhanuka Agritech Ltd reads as topping out on its fundamental arc. Topping out — revenue, profit and EPS growth have decelerated hard (revenue growth +15.0% at its peak → +0.9% latest) while ROCE still reads 24.6%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +15.7% in FY25, profit +24.3% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
25%57%20%39%14%21%7.8%2.8%1.9%−15%%%15.7%24.3%FY15FY20FY25
25%57%20%39%14%21%7.8%2.8%1.9%−15%%%15.7%24.3%FY15FY20FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over, profit rolling over
RevenueProfitEPS
17%28%13%19%8.3%10%4.0%1.1%−0.3%−7.8%%%0.9%−5.3%−5.1%Mar 23Jun 24Dec 25
17%28%13%19%8.3%10%4.0%1.1%−0.3%−7.8%%%0.9%−5.3%−5.1%Mar 23Jun 24Dec 25
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
30%29%27%26%24%%24.6%Mar 23Sep 23Jun 24Mar 25Dec 25
30%29%27%26%24%%24.6%Mar 23Jun 24Dec 25
Revenue growth
Falling
latest +0.9% · span +0.9% to +15.8%
Profit growth
Falling
latest −5.3% · span −5.3% to +24.7%
EPS growth
Falling
latest −5.1% · span −5.1% to +25.4%
ROCE
Rolling over
latest 24.6% · span 24.6%–29.6%

Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+15.7%+11.2%+12.7%+10.0%
Profit+24.3%+12.4%+16.1%+10.9%
EPS+25.6%+13.7%+17.3%+12.0%
Share price−37.9%+10.8%+1.5%+4.4%
Revenue YoY (Dec 25)
−7.9%
latest quarter vs a year ago
Profit YoY (Dec 25)
−27.3%
latest quarter vs a year ago
Revenue 10y
10.0%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

46.6/100 — rank 13 of 24 in Pesticides/Agrochemicals · 96% evidence confidence

Dhanuka Agritech Ltd scores 46.6 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 13. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 8.3 + 19.1 + 13 + 6.2 = 46.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Dhanuka Agritech Ltd reported ₹410 Cr of revenue in the Dec 25 quarter, −7.9% year on year. Over 10 years it has compounded at 10.0% a year. The last full year, FY25, came in at ₹2,035 Cr. The last four reported quarters add to ₹1,978 Cr.

FY25 revenue came in at ₹2,035 Cr (+15.7% on the year), capping 10 years at 10.0% compound. The latest quarter (Dec 25) printed ₹410 Cr, −7.9% year on year.

FY25 revenue ₹2,035 Cr (+15.7% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
10.0% a year over 10 years
RevenueYoY growth
2.2k25%1.6k20%1.1k14%5497.8%01.9%₹ Cr%₹2,03515.7%FY15FY20FY25
2.2k25%1.6k20%1.1k14%5497.8%01.9%₹ Cr%₹2,03515.7%FY15FY20FY25
Dec 25: ₹410 Cr (−7.9% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
70637%53025%35313%1770.0%0−12%₹ Cr%₹410−7.9%Mar 23Jun 24Dec 25
70637%53025%35313%1770.0%0−12%₹ Cr%₹410−7.9%Mar 23Jun 24Dec 25

Pace check: the last four quarters averaged +2.6% growth against the decade's 10.0% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +0.9% over the last 4 quarters against +6.0%/yr over the last 8 — rolling over; TTM profit −5.3% vs +4.2%/yr — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Dhanuka Agritech Ltd's operating margin is 14.0% in the Dec 25 quarter, −3.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 12 fiscal years the operating margin has ranged 15.0% to 20.0%. The current quarter is running below every full year in that window.

The latest quarter's operating margin is 14.0%, −3.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 15.0%–20.0%, and FY25's 20.0% is the top of that band — a record year.

Why the margin moved: operating margin went +3.1 pp year on year while gross margin went −0.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY25: 20.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 12-year window.
the widest a 15.0–20.0% band over 12 years
operating marginYoY change (pp)
20%4.5%19%2.7%18%1.0%16%−0.7%15%−2.5%%%20%1%FY14FY19FY25
20%4.5%19%2.7%18%1.0%16%−0.7%15%−2.5%%%20%1%FY14FY19FY25
Dec 25: 14.0% operating margin (−3.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
26%5.6%22%3.3%19%1.0%15%−1.3%11%−3.6%%%14%−3%Mar 23Jun 24Dec 25
26%5.6%22%3.3%19%1.0%15%−1.3%11%−3.6%%%14%−3%Mar 23Jun 24Dec 25
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Dhanuka Agritech Ltd earned ₹40.0 Cr of net profit in the Dec 25 quarter, −27.3% year on year. Full-year FY25 profit was ₹297 Cr. The 10-year compound rate is 10.9%. That is 9.8% of the quarter's revenue. The same quarter a year earlier earned ₹55.0 Cr.

Dec 25 profit was ₹40.0 Cr, −27.3% year on year. On the full year, FY25 printed ₹297 Cr (+24.3%), and the 10-year compound rate is 10.9%.

FY25 profit ₹297 Cr (+24.3% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
10.9% a year over 10 years
Net profitYoY growth
32154%24137%16020%802.3%0−15%₹ Cr%₹29724.3%FY15FY20FY25
32154%24137%16020%802.3%0−15%₹ Cr%₹29724.3%FY15FY20FY25
Dec 25: ₹40.0 Cr (−27.3% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
12755%9631%647.9%32−16%0−39%₹ Cr%₹40−27.3%Mar 23Jun 24Dec 25
12755%9631%647.9%32−16%0−39%₹ Cr%₹40−27.3%Mar 23Jun 24Dec 25

🚨 Why profit moved: revenue contributed −7.9% and the margin −3.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit −1.1% vs revenue +2.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 69% of Dhanuka Agritech Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY25 that was ₹263 Cr of operating cash against ₹297 Cr of profit. After ₹202 Cr of capital spending, ₹61.0 Cr was left as free cash.

FY25: operating cash of ₹263 Cr against reported profit of ₹297 Cr, leaving free cash of ₹61.0 Cr after ₹202 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 69% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO ₹263 Cr vs profit ₹297 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 11-year window, annual resolution.
69% of 3-year profit arrived as cash
Operating cashNet profitFree cash
321241160800₹ Cr₹263₹297₹61FY15FY20FY25
321241160800₹ Cr₹263₹297₹61FY15FY20FY25
FY25: CFO = 89% of profit (three-year rate 69%) Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash.
Conversion100%
141%106%72%37%2.5%%89%FY15FY20FY25
141%106%72%37%2.5%%89%FY15FY20FY25

🚨 Why conversion sits at 69%: the cash cycle stretched 12 days between FY20 and FY25 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 12 days — the next section's job is to find where the cash is stuck.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Dhanuka Agritech Ltd's cash conversion cycle runs 168 days in FY25, up from 156 days in FY20. Capital spending ran ₹420 Cr over the last 3 years. At FY25 sales of ₹2,035 Cr each day of that cycle holds about ₹5.6 Cr, so roughly ₹937 Cr sits inside the business at any moment.

FY25: debtors at 82 days, inventory at 132 days — roughly 4.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 168 days, looser than FY20's 156.

The full loop: cash goes out to suppliers and production on day 0; stock waits 132 days to sell; customers pay about 82 days after that; and suppliers themselves are paid at 46 days — netting out to the 168-day cycle.

In money terms: at FY25 sales of ₹2,035 Cr, each day of the cycle holds about ₹5.6 Cr — so the 168-day loop keeps roughly ₹937 Cr sitting inside the business at any moment.

FY25: a 168-day cash cycle Debtor days, inventory days, payable days and the cash conversion cycle by fiscal year. 12-year window.
+12 days vs FY20
Cash cycleInventory daysDebtor daysPayable days
2672051448321days168d132d82d46dFY14FY16FY19FY22FY25
2672051448321days168d132d82d46dFY14FY19FY25

On the investment side: capital spending of ₹420 Cr over the last 3 fiscal years against ₹114 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹9.0 Cr (FY25) — capacity paid for but not yet earning.

FY25: capex ₹202 Cr, work-in-progress ₹9.0 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
a build-out
CapexWork-in-progress
21815910142−17₹ Cr₹202₹9FY15FY17FY20FY22FY25
21815910142−17₹ Cr₹202₹9FY15FY20FY25

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

10 · Return on capital

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Dhanuka Agritech Ltd earns a ROCE of 28% in FY25. That is up from a trough of 23% in FY19. Return on invested capital clears the cost of that capital by +4.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 14.6% net margin on 1.13× asset turns.

FY25 ROCE is 28%, recovered from a FY19 trough of 23% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 14.6% net margin × 1.13× asset turns × 1.28× balance-sheet leverage ≈ 21.1% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 16.8% − 12.0% = a +4.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

FY25: ROCE 28% Return on capital employed by fiscal year, % (line); ROIC by fiscal year, % (line). 12-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the climb back from FY19's 23%
ROCEROIC (annual)WACC
38%31%24%17%10%%28%21.4%FY14FY19FY25
38%31%24%17%10%%28%21.4%FY14FY19FY25
Q4 FY26: ROCE 19.6% (TTM) vs WACC 12.0% Trailing-twelve-month ROCE and ROIC, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROCE (TTM)ROIC (TTM)WACC
26%22%18%15%11%%19.6%17.6%Q1 FY24Q2 FY25Q4 FY26
26%22%18%15%11%%19.6%17.6%Q1 FY24Q2 FY25Q4 FY26
11 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Dhanuka Agritech Ltd carries total debt of ₹31.0 Cr against shareholder equity of ₹1,682 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.03 in FY22 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹31.0 Cr against shareholder equity of ₹1,682 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.03 (FY22) to 0.02 (FY26). The returns on this page are earned, not borrowed.

FY26: debt ₹31.0 Cr at 0.02× equity Total debt by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
800.052×600.044×400.035×200.026×00.018×₹ Cr×₹310.02×FY22FY24FY26
800.052×600.044×400.035×200.026×00.018×₹ Cr×₹310.02×FY22FY24FY26
Mar 26: debt ₹31.0 Cr, debt-to-equity 0.02 Total debt per quarter, ₹ Cr (bars); debt-to-equity, × (line). Last 12 quarters. India reports the full balance sheet half-yearly, so the intervening quarter carries the prior reading forward.
Total debt (quarterly)Debt-to-equity
910.07×680.06×450.05×230.03×00.02×₹ Cr×₹310.02×Jun 23Sep 24Mar 26
910.07×680.06×450.05×230.03×00.02×₹ Cr×₹310.02×Jun 23Sep 24Mar 26
12 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Dhanuka Agritech Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved −0.4 points over the same window, to 69.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: −0.6 points over 8 quarters to 18.7%; Promoters: −0.4 points over 8 quarters to 69.8%; Foreign institutions: +0.1 points over 8 quarters to 1.6%.

Fiscal-year ends: promoters −0.5 pts from Mar 24 to Mar 26 Shareholding at each fiscal-year end (March quarter), % of the company. 3 year-ends held.
PromotersForeign inst.Domestic inst.Public
76%56%36%16%−4.0%%69.7%1.9%19.4%8.9%Mar 24Mar 25Mar 26
76%56%36%16%−4.0%%69.7%1.9%19.4%8.9%Mar 24Mar 25Mar 26
A quiet register: no holder moved a full point in two years Shareholding by holder class, % of the company, quarterly, last 13 quarters.
PromotersForeign inst.Domestic inst.Public
76%56%36%16%−4.2%%69.8%1.6%18.7%9.8%Jun 23Dec 24Jun 26
76%56%36%16%−4.2%%69.8%1.6%18.7%9.8%Jun 23Dec 24Jun 26
13 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Dhanuka Agritech Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

14 · Related companies · Pesticides/Agrochemicals
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Titan Biotech Ltd524717 69.3/100Favorable setup78% evidence ASLEEP 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 6.9 pp 83% evidence 20.2/25 ROCE 22.8% · OPM 19.9% 76% evidence 6.0/20 P/E 57.8× · PEG — 50% evidence 14.0/20 RS sector 41.7% · RS bench 39.3% · 1Y 371.1%5 of 12 weeks ahead 100% evidence
Exact sum: 29.1 + 20.2 + 6 + 14 = 69.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Sharda Cropchem LtdSHARDACROP 65.3/100Favorable setup97% evidence ASLEEP 23.7/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 95% evidence 18.5/25 ROCE 30.2% · OPM 17% 95% evidence 19.2/20 P/E 11.8× · PEG 0.26 100% evidence 3.9/20 RS sector -10.9% · RS bench -13.7% · 1Y -24.6%0 of 12 weeks ahead 100% evidence
Exact sum: 23.7 + 18.5 + 19.2 + 3.9 = 65.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.9% and the one-year return is -24.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
3Punjab Chemicals & Crop Protection LtdPUNJABCHEM 61.8/100Mixed-positive evidence81% evidence ASLEEP 22.7/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence 18.3/25 ROCE 18.6% · OPM 12% 95% evidence 12.1/20 P/E 21× · PEG — 50% evidence 8.7/20 RS sector -6.2% · RS bench -2.6% · 1Y -13.2%1 of 10 weeks ahead 70% evidence
Exact sum: 22.7 + 18.3 + 12.1 + 8.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Bayer CropScience LtdBAYERCROP 61.7/100Mixed-positive evidence70% evidence ASLEEP 21.4/35 Revenue 3.7% · PAT 21.7% · OPM change 2.1 pp 83% evidence 19.1/25 ROCE 20.1% · OPM 18.4% 95% evidence 8.5/20 P/E 387× · PEG — 15% evidence 12.7/20 RS sector 9.4% · RS bench -10.7% · 1Y -33.2%0 of 10 weeks ahead 70% evidence
Exact sum: 21.4 + 19.1 + 8.5 + 12.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Dharmaj Crop Guard LtdDHARMAJ 61.1/100Mixed-positive evidence62% evidence TURNING 23.8/35 Revenue 19.6% · PAT 56.9% · OPM change 2.7 pp 62% evidence 12.9/25 ROCE 16.4% · OPM 4.5% 95% evidence 10.6/20 P/E 16.6× · PEG — 15% evidence 13.8/20 RS sector 5% · RS bench -2.5% · 1Y -13.2%4 of 10 weeks ahead 70% evidence
Exact sum: 23.8 + 12.9 + 10.6 + 13.8 = 61.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Advance Agrolife LtdADVANCE 56.3/100Thin evidence · provisional56% evidence TURNING 21.4/35 Revenue 27% · PAT 37.6% · OPM change 4.3 pp 83% evidence 14.8/25 ROCE 19.3% · OPM 10.8% 95% evidence 10.1/20 P/E 22.8× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence
Exact sum: 21.4 + 14.8 + 10.1 + 10 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7UPL LtdUPL 54.2/100Mixed-positive evidence90% evidence ASLEEP 20.6/35 Revenue 11.2% · PAT 100% · OPM change -1 pp 88% evidence 9.3/25 ROCE 10.1% · OPM 19% 100% evidence 12.5/20 P/E 28.3× · PEG 0.5 100% evidence 11.8/20 RS sector 4.9% · RS bench -12.2% · 1Y -16.3%0 of 10 weeks ahead 70% evidence
Exact sum: 20.6 + 9.3 + 12.5 + 11.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8India Pesticides LtdIPL 54.0/100Mixed-positive evidence81% evidence TURNING 20.0/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence 13.6/25 ROCE 16.7% · OPM 14% 95% evidence 14.1/20 P/E 16.5× · PEG — 50% evidence 6.3/20 RS sector -11.9% · RS bench -12.1% · 1Y -27.3%4 of 11 weeks ahead 70% evidence
Exact sum: 20 + 13.6 + 14.1 + 6.3 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Jubilant Ingrevia LtdJUBLINGREA 52.7/100Mixed-positive evidence93% evidence FADING 18.2/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence 10.2/25 ROCE 11.4% · OPM 15% 100% evidence 6.4/20 P/E 36.8× · PEG 2.37 65% evidence 17.9/20 RS sector 11.8% · RS bench 7.8% · 1Y -5.6%6 of 12 weeks ahead 100% evidence
Exact sum: 18.2 + 10.2 + 6.4 + 17.9 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Bharat Rasayan LtdBHARATRAS 51.6/100Mixed-positive evidence77% evidence ASLEEP 17.1/35 Revenue 5.8% · PAT 3.5% · OPM change 4 pp 83% evidence 16.5/25 ROCE 17.4% · OPM 16% 95% evidence 14.7/20 P/E 13.3× · PEG — 50% evidence 3.3/20 RS sector -33.2% · RS bench -34.6% · 1Y -51.5%0 of 11 weeks ahead 70% evidence
Exact sum: 17.1 + 16.5 + 14.7 + 3.3 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Bhagiradha Chemicals & Industries LtdBHAGCHEM 51.0/100Mixed-positive evidence88% evidence TURNING 23.6/35 Revenue 21.7% · PAT 31.1% · OPM change 7.3 pp 65% evidence 5.8/25 ROCE 4.5% · OPM 12.3% 100% evidence 2.0/20 P/E 207× · PEG 3.04 100% evidence 19.6/20 RS sector 22.5% · RS bench 17.9% · 1Y -0.7%11 of 12 weeks ahead 100% evidence
Exact sum: 23.6 + 5.8 + 2 + 19.6 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12GSP Crop Science LtdGSPCROP 50.4/100Thin evidence · provisional59% evidence TURNING 16.5/35 Revenue 21.2% · PAT 37.8% · OPM change -4 pp 88% evidence 14.3/25 ROCE 19% · OPM 9% 100% evidence 9.6/20 P/E 26.8× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence
Exact sum: 16.5 + 14.3 + 9.6 + 10 = 50.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Dhanuka Agritech Ltdthis pageDHANUKA 46.6/100Mixed-negative evidence96% evidence ASLEEP 8.3/35 Revenue 0.9% · PAT -5.3% · OPM change -2.5 pp 88% evidence 19.1/25 ROCE 28.3% · OPM 22.5% 100% evidence 13.0/20 P/E 15.6× · PEG 1.72 100% evidence 6.2/20 RS sector -12.4% · RS bench -16.2% · 1Y -40.9%4 of 12 weeks ahead 100% evidence
Exact sum: 8.3 + 19.1 + 13 + 6.2 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Sumitomo Chemical India LtdSUMICHEM 45.4/100Mixed-negative evidence94% evidence TURNING 12.1/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence 19.0/25 ROCE 22.1% · OPM 22% 100% evidence 4.0/20 P/E 44.6× · PEG 4 100% evidence 10.3/20 RS sector -8.2% · RS bench 6% · 1Y -12.8%9 of 10 weeks ahead 70% evidence
Exact sum: 12.1 + 19 + 4 + 10.3 = 45.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
15Rallis India LtdRALLIS 45.3/100Mixed-negative evidence91% evidence ASLEEP 16.1/35 Revenue 7.3% · PAT -28.4% · OPM change 2.6 pp 95% evidence 9.3/25 ROCE 12.8% · OPM 15.2% 95% evidence 11.4/20 P/E 26.7× · PEG 0.89 100% evidence 8.5/20 RS sector -1.8% · RS bench -20.7% · 1Y -39.2%0 of 10 weeks ahead 70% evidence
Exact sum: 16.1 + 9.3 + 11.4 + 8.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16NACL Industries LtdNACLIND 44.9/100Mixed-negative evidence94% evidence TURNING 28.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence 4.4/25 ROCE 8.1% · OPM 11% 100% evidence 3.8/20 P/E 171× · PEG 2.02 100% evidence 8.6/20 RS sector -12.5% · RS bench 3.8% · 1Y -26.9%10 of 10 weeks ahead 70% evidence
Exact sum: 28.1 + 4.4 + 3.8 + 8.6 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Astec Lifesciences LtdASTEC 44.9/100Mixed-negative evidence63% evidence ASLEEP 23.3/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence 2.6/25 ROCE -5.4% · OPM -0.8% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 9.0/20 RS sector -3.5% · RS bench -9.3% · 1Y -27.2%7 of 10 weeks ahead 70% evidence
Exact sum: 23.3 + 2.6 + 10 + 9 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Meghmani Organics LtdMOL 44.3/100Mixed-negative evidence74% evidence TURNING 20.6/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence 9.4/25 ROCE 6.7% · OPM 18% 95% evidence 10.2/20 P/E 21.3× · PEG — 15% evidence 4.1/20 RS sector -33.7% · RS bench -13.6% · 1Y -42.8%3 of 10 weeks ahead 70% evidence
Exact sum: 20.6 + 9.4 + 10.2 + 4.1 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Insecticides India LtdINSECTICID 43.8/100Mixed-negative evidence77% evidence ASLEEP 11.9/35 Revenue 7% · PAT -1.4% · OPM change -2 pp 83% evidence 13.0/25 ROCE 15.8% · OPM 6% 95% evidence 11.7/20 P/E 13.5× · PEG — 50% evidence 7.2/20 RS sector -8.5% · RS bench -9.5% · 1Y -38.7%7 of 10 weeks ahead 70% evidence
Exact sum: 11.9 + 13 + 11.7 + 7.2 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Excel Industries LtdEXCELINDUS 43.1/100Mixed-negative evidence70% evidence TURNING 14.4/35 Revenue 12% · PAT -11.8% · OPM change 0 pp 83% evidence 8.6/25 ROCE 6.1% · OPM 8% 95% evidence 10.9/20 P/E 16.4× · PEG — 15% evidence 9.2/20 RS sector -4.6% · RS bench -2.6% · 1Y -27.3%2 of 10 weeks ahead 70% evidence
Exact sum: 14.4 + 8.6 + 10.9 + 9.2 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21Epigral LtdEPIGRAL 41.3/100Mixed-negative evidence94% evidence ASLEEP 6.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence 14.3/25 ROCE 15.5% · OPM 25% 100% evidence 16.5/20 P/E 17.3× · PEG 0.43 100% evidence 4.0/20 RS sector -32.9% · RS bench -17.5% · 1Y -40.9%7 of 10 weeks ahead 70% evidence
Exact sum: 6.5 + 14.3 + 16.5 + 4 = 41.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
22P I Industries LtdPIIND 40.9/100Mixed-negative evidence90% evidence ASLEEP 6.6/35 Revenue -15.9% · PAT -20.5% · OPM change -3 pp 88% evidence 15.5/25 ROCE 15% · OPM 22% 100% evidence 10.6/20 P/E 34.7× · PEG 1.71 100% evidence 8.2/20 RS sector -3.4% · RS bench -15.3% · 1Y -32.8%0 of 10 weeks ahead 70% evidence
Exact sum: 6.6 + 15.5 + 10.6 + 8.2 = 40.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Best Agrolife LtdBESTAGRO 29.7/100Adverse evidence81% evidence TURNING 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence 9.0/25 ROCE 5.2% · OPM 20% 95% evidence 7.0/20 P/E 22.9× · PEG — 50% evidence 5.8/20 RS sector -30.7% · RS bench -8.5% · 1Y -36.9%1 of 11 weeks ahead 70% evidence
Exact sum: 7.9 + 9 + 7 + 5.8 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Heranba Industries LtdHERANBA 25.7/100Adverse evidence65% evidence ASLEEP 11.7/35 Revenue 13.1% · PAT -80% · OPM change -2.7 pp 62% evidence 1.2/25 ROCE -1.6% · OPM -7% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 2.8/20 RS sector -22% · RS bench -25.7% · 1Y -51.8%0 of 12 weeks ahead 100% evidence
Exact sum: 11.7 + 1.2 + 10 + 2.8 = 25.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

15 · Frequently asked questions

Frequently asked questions

What is Dhanuka Agritech Ltd's share price today?

Dhanuka Agritech Ltd trades at ₹1,022, −37.9% over the past year. The company is valued at ₹4,555 Cr. The stock sits at 15% of its 52-week range of ₹936–₹1,527, −10.7% versus its 200-day average. On the tape, the price is in a downtrend, 40 weeks in. — as of 31 July 2026.

What were Dhanuka Agritech Ltd's latest quarterly results?

Dhanuka Agritech Ltd reported revenue of ₹410 Cr and net profit of ₹40.0 Cr for the Dec 25 quarter. Revenue fell 7.9% and profit fell 27.3% year on year. Earnings per share were ₹8.87. The operating margin was 14.0%, 3.0 pp lower than a year earlier. — as of 31 July 2026.

What is Dhanuka Agritech Ltd's revenue?

Dhanuka Agritech Ltd reported revenue of ₹410 Cr in the Dec 25 quarter, −7.9% year on year. For the full FY25 fiscal year, revenue was ₹2,035 Cr (+15.7%). Over the last 10 years revenue compounded at 10.0% a year. — as of 31 July 2026.

What is Dhanuka Agritech Ltd's profit?

Dhanuka Agritech Ltd earned ₹40.0 Cr of net profit in the Dec 25 quarter, −27.3% year on year. Full-year FY25 profit was ₹297 Cr. The operating margin ran 14.0% in the latest quarter. — as of 31 July 2026.

What is Dhanuka Agritech Ltd's market cap?

Dhanuka Agritech Ltd's market capitalisation is ₹4,555 Cr at a share price of ₹1,022. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.

What is Dhanuka Agritech Ltd's P/E ratio?

Dhanuka Agritech Ltd trades at a P/E of 15.6×, at the 15th percentile of its own 11-year range, against a long-run median of 19.2×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.

Does Dhanuka Agritech Ltd pay a dividend?

Yes — Dhanuka Agritech Ltd's dividend payout was 3% of profit in FY25, and it recorded a payout in each of its last 12 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.

Is Dhanuka Agritech Ltd overvalued?

On its own history, Dhanuka Agritech Ltd looks cheap against its own history: its P/E of 15.6× has been cheaper only 15% of the time in 11 years (long-run median 19.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.

Is Dhanuka Agritech Ltd growing?

Not right now — Dhanuka Agritech Ltd's latest numbers are shrinking: latest-quarter revenue −7.9% year on year, profit −27.3%, and the margin −3.0 pp at 14.0%. The 10-year compound rates are 10.0% (revenue) and 10.9% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.

How is Dhanuka Agritech Ltd performing?

Dhanuka Agritech Ltd is in a downtrend, 40 weeks in. Its latest quarter's revenue fell 7.9% and profit fell 27.3% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 31 July 2026.

What stage is Dhanuka Agritech Ltd in?

Topping out — revenue, profit and EPS growth have decelerated hard (revenue growth +15.0% at its peak → +0.9% latest) while ROCE still reads 24.6%. The read comes from the last 12 quarters of growth (revenue growth +0.9% latest, profit growth −5.3% latest, eps growth −5.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.

Is Dhanuka Agritech Ltd in an uptrend?

No — the price is in a downtrend (week 40 of stage 4), trading −10.7% versus its 200-day average and at 15% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.

Is Dhanuka Agritech Ltd beating the market?

Not lately — on a trailing-13-week view Dhanuka Agritech Ltd is currently behind the NIFTY 500 (9 weeks and counting; last ahead the week of 2026-06-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +84% against the NIFTY 500's +274% — behind the index over the full window. — as of 31 July 2026.

Will Dhanuka Agritech Ltd's share price go up?

This page publishes no price forecast for Dhanuka Agritech Ltd. What it measures instead: the share price is ₹1,022, the price is in a downtrend 40 weeks in. Its P/E of 15.6× sits at the 15th percentile of its own 11-year range. — as of 31 July 2026.

Who owns Dhanuka Agritech Ltd?

Promoters hold 69.8% of Dhanuka Agritech Ltd, foreign institutions 1.6%, domestic institutions 18.7% and the public 9.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.

Does Dhanuka Agritech Ltd have too much debt?

No — Dhanuka Agritech Ltd's debt-to-equity is 0.05, and operating profit covers the interest bill 83×. FY25 borrowings were ₹74.0 Cr against equity of ₹1,403 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.

What is Dhanuka Agritech Ltd's capex?

Dhanuka Agritech Ltd spent ₹420 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹202 Cr, with ₹9.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.

What is Dhanuka Agritech Ltd's cash flow?

Dhanuka Agritech Ltd generated ₹263 Cr of operating cash flow in FY25 and ₹61.0 Cr of free cash flow after ₹202 Cr of capital spending. Reported profit that year was ₹297 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.

Is Dhanuka Agritech Ltd's profit real cash?

Mostly — over the last 3 fiscal years, 69% of Dhanuka Agritech Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹263 Cr against reported profit of ₹297 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.

Where is Dhanuka Agritech Ltd in its business cycle?

Dhanuka Agritech Ltd's FY25 operating margin was 20.0%, against a 12-year band of 15.0%–20.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 14.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.

What could break the Dhanuka Agritech Ltd story?

The sharpest disagreement: annual EPS moved +25.6% against a −37.9% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.

Is Dhanuka Agritech Ltd a stock worth studying right now?

This is not investment advice. The machine read: Dhanuka Agritech Ltd is cheap for a reason. The P/E sits at the 15th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI